Femasys Secures Spanish Distribution Partnerships

Femasys Inc. has found Spanish distributors for its CE-marked products, including FemaSeed and FemVue. 

Comercial Medico Quirurigca SA (CMQ) will distribute the products in northern Spain while Durgalab will distribute them in the south. Spain is the first EU country where Femasys has identified distributors and began marketing its products.
 
“[This] marks a significant step in our global expansion and reinforces our mission to empower women across the world with new, innovative and superior healthcare solutions,” Femasys Founder/CEO Kathy-Lee Sepsick commented. “Our distribution partners have extensive expertise in women’s healthcare and a strong understanding of the value of our infertility portfolio. Their commitment to purchase a minimum of $1.3 million of FemaSeed over the next year gives us great confidence in their ability to expand access to our affordable and effective solutions for women.”
 
Spain has the most in-vitro fertilization (IVF) clinics with 244 facilities in Europe, according to the European registries by the European Society of Human Reproduction and Embryology.¹ Additionally, Spain ranks second in intrauterine (IUI) insemination cycles using a husband’s sperm and holds the top position for IUI cycles using donor sperm.

“It is an honor to partner with Femasys to bring the latest technology for infertility treatment that is more cost-effective than IVF or ICSI and an improvement to traditional IUI to the Spain market,” CMQ Founder/CEO Jordi Pié said. “We have been preparing as we awaited the availability of Femasys’ products with the CE mark under MDR and are thrilled to provide FemaSeed along with the other diagnostic products.”

Femasys is a biomedical company focused on addressing significant unmet needs of women worldwide with in-office, accessible therapeutic and diagnostic solutions, including a revolutionary product candidate and U.S. Food and Drug Administration (FDA)-cleared products. FemaSeed Intratubal Insemination, an infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada and Europe. FemBloc permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the United States, Canada, Europe, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Its diagnostic products include FemVue and FemVue MINI for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv, an endocervical tissue sampler for cervical cancer diagnosis. 

Reference
¹ ART in Europe, 2019: results generated from European registries by ESHRE, Human Reproduction, 2023, 38(12), 2321–2338, https://doi.org/10.1093/humrep/dead197, October 17, 2023.